Steven Yip

1.0k total citations
54 papers, 527 citations indexed

About

Steven Yip is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Steven Yip has authored 54 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Steven Yip's work include Prostate Cancer Treatment and Research (31 papers), PARP inhibition in cancer therapy (15 papers) and Cancer Genomics and Diagnostics (12 papers). Steven Yip is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), PARP inhibition in cancer therapy (15 papers) and Cancer Genomics and Diagnostics (12 papers). Steven Yip collaborates with scholars based in Canada, United States and Japan. Steven Yip's co-authors include Kim N., Alexander W. Wyatt, Evan W. Warner, Michael Kolinsky, Pinaki Bose, Nicholas Jette, Susan P. Lees‐Miller, Mehul Kumar, Gareth J. Williams and Ajjai Alva and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Steven Yip

49 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Yip Canada	12	317	256	207	167	52	54	527
Liancheng Fan China	15	402 1.3×	270 1.1×	217 1.0×	201 1.2×	79 1.5×	38	691
João D. Barros‐Silva Portugal	14	389 1.2×	218 0.9×	320 1.5×	206 1.2×	65 1.3×	22	672
Milan Mangeshkar United States	9	369 1.2×	289 1.1×	217 1.0×	165 1.0×	32 0.6×	17	655
Òscar Reig Spain	13	303 1.0×	218 0.9×	190 0.9×	153 0.9×	52 1.0×	56	562
Katherine A. Scilla United States	11	290 0.9×	363 1.4×	136 0.7×	162 1.0×	32 0.6×	25	583
Catherine J. Kennedy Australia	13	176 0.6×	194 0.8×	234 1.1×	119 0.7×	44 0.8×	25	560
Mingwei Ma China	10	255 0.8×	286 1.1×	120 0.6×	187 1.1×	54 1.0×	47	574
Anuradha Chougule India	13	481 1.5×	357 1.4×	142 0.7×	162 1.0×	27 0.5×	53	620
Ines Figueiredo United Kingdom	11	356 1.1×	237 0.9×	185 0.9×	232 1.4×	93 1.8×	26	576
Guoping Ren China	15	314 1.0×	181 0.7×	250 1.2×	217 1.3×	22 0.4×	40	654

Countries citing papers authored by Steven Yip

Since Specialization

Citations

This map shows the geographic impact of Steven Yip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Yip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Yip more than expected).

Fields of papers citing papers by Steven Yip

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Yip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Yip. The network helps show where Steven Yip may publish in the future.

Co-authorship network of co-authors of Steven Yip

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Yip. A scholar is included among the top collaborators of Steven Yip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Yip. Steven Yip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yip, Steven, Winson Y. Cheung, Armen Aprikian, et al.. (2025). Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada. Future Oncology. 21(10). 1197–1207. 1 indexed citations

Chi, K.N., Fred Saad, Kejia Ding, et al.. (2025). LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21. Annals of Oncology. 36. S1630–S1631.

Azad, Arun, Karim Fizazi, Douglas Laird, et al.. (2024). Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5020–5020.

Cook, Sarah, Kosuke Takemura, Daniel Yick Chin Heng, et al.. (2024). Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. 23(1). 102274–102274. 1 indexed citations

Fizazi, Karim, Whijae Roh, Arun Azad, et al.. (2024). Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5021–5021.

Yip, Steven, Karim Fizazi, Douglas Laird, et al.. (2024). Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5023–5023. 1 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

Karim, Safiya, Dylan E. O’Sullivan, Christopher J.D. Wallis, et al.. (2023). A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS). Current Oncology. 30(9). 8149–8158. 5 indexed citations

Lee‐Ying, Richard M., Dylan E. O’Sullivan, Nimira Alimohamed, et al.. (2022). Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study. CMAJ Open. 10(3). E633–E642. 2 indexed citations

10.

Warner, Evan W., Cameron Herberts, Simon Fu, et al.. (2021). BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research. 27(6). 1650–1662. 52 indexed citations

11.

Walker, S. R., Sunita Ghosh, Julie Livingstone, et al.. (2021). Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. European Urology Open Science. 29. 93–101. 4 indexed citations

12.

Li, Haocheng, Cheng‐Han Lee, Steven Yip, et al.. (2021). Utilization of Mutational Analysis (MA) in Gastrointestinal Stromal Tumor (GIST) Management in British Columbia (BC) Between January 2008 to December 2017: a Retrospective Population-Based Study. Journal of Gastrointestinal Cancer. 53(3). 709–717. 2 indexed citations

13.

Yip, Steven, Daniel E. Meyers, Jeff Sisler, et al.. (2020). Oncology education for family medicine residents: a national needs assessment survey. BMC Medical Education. 20(1). 283–283. 9 indexed citations

14.

Gordevičius, Juozas, Daniel E. Groot, Steven Yip, et al.. (2018). Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients. Clinical Cancer Research. 24(14). 3317–3324. 35 indexed citations

15.

Francini, Edoardo, Steven Yip, Haocheng Li, et al.. (2017). Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer. 16(2). 130–134. 16 indexed citations

16.

Yip, Steven, et al.. (2017). Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. Clinical Genitourinary Cancer. 16(3). e637–e644. 7 indexed citations

17.

Yip, Steven, Frede Donskov, Anna Paola Fraccon, et al.. (2017). Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). PubMed. 1(1). 41–47. 10 indexed citations

18.

Francini, Edoardo, Steven Yip, Neesar Ahmed, et al.. (2017). Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry. Annals of Oncology. 28. v278–v279. 3 indexed citations

19.

Yip, Steven, et al.. (2017). Real world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio.. Journal of Clinical Oncology. 35(15_suppl). e16020–e16020. 2 indexed citations

20.

Yip, Steven, et al.. (2001). Down-regulation of Na-K-Cl Cotransport by Protein Kinase C is Mediated by Protein Phosphatase 1 in Pigmented Ciliary Epithelial Cells. Experimental Eye Research. 72(4). 371–379. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact